This post-hoc analysis provides the first evidence that the new treatment is associated with a significant improvement in functional outcome
Online PR News – 09-November-2015 – Braincure-Biotech.com announced that a post-hoc analysis showed in a new and not released treatment increases the probability of achieving sustained improvement in physical disability over two years when compared to placebo. This post-hoc analysis provides the first evidence that the new treatment is associated with a significant improvement in functional outcome, rather than only slowing or preventing progression of disability, in those living with relapsing multiple brain sclerosis.
These results show that patients treated with this new technique are significantly more likely to experience a sustained improvement in disability compared to placebo patients. This finding from a post-hoc analysis of the pivotal trial supports both the earlier findings from the trial that the treatment is associated with an improvement in quality of life as well as anecdotal evidence of recovery of function in some patients. said Liao Ming, MD, Head of Department of Neurology at Braincure Biotech. While other therapies have shown a slowing of progression in disability, this analysis represents the first evidence supporting a sustained improvement in function associated with an approved disease modifying therapy.
The proportion of patients exhibiting sustained improvements in physical disability in the study was determined based upon the Expanded Disability Status Scale (EDSS) over two years in patients with relapsing MS. EDSS is one of the oldest and most widely utilized methods of quantifying disability in MS.
About Braincure Biotech